BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 21600284)

  • 1. The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk.
    Williams-Brown MY; Salih SM; Xu X; Veenstra TD; Saeed M; Theiler SK; Diaz-Arrastia CR; Salama SA
    J Steroid Biochem Mol Biol; 2011 Sep; 126(3-5):78-86. PubMed ID: 21600284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential actions of estrogen and SERMs in regulation of the actin cytoskeleton of endometrial cells.
    Flamini MI; Sanchez AM; Goglia L; Tosi V; Genazzani AR; Simoncini T
    Mol Hum Reprod; 2009 Oct; 15(10):675-85. PubMed ID: 19541800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus.
    Stygar D; Muravitskaya N; Eriksson B; Eriksson H; Sahlin L
    Reprod Biol Endocrinol; 2003 May; 1():40. PubMed ID: 12777179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth-stimulatory and transcriptional activation properties of raloxifene in human endometrial Ishikawa cells.
    Barsalou A; Dayan G; Anghel SI; Alaoui-Jamali M; Van de Velde P; Mader S
    Mol Cell Endocrinol; 2002 Apr; 190(1-2):65-73. PubMed ID: 11997179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.
    Gielen SC; Burger CW; Kühne LC; Hanifi-Moghaddam P; Blok LJ
    J Soc Gynecol Investig; 2005 Oct; 12(7):e55-67. PubMed ID: 16202921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrospray ionization-tandem mass spectrometry and 32P-postlabeling analyses of tamoxifen-DNA adducts in humans.
    Beland FA; Churchwell MI; Doerge DR; Parkin DR; Malejka-Giganti D; Hewer A; Phillips DH; Carmichael PL; Gamboa da Costa G; Marques MM
    J Natl Cancer Inst; 2004 Jul; 96(14):1099-104. PubMed ID: 15265972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.
    Dardes RC; Schafer JM; Pearce ST; Osipo C; Chen B; Jordan VC
    Gynecol Oncol; 2002 Jun; 85(3):498-506. PubMed ID: 12051881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endometrial effects of SERMs.
    Cano A; Hermenegildo C
    Hum Reprod Update; 2000; 6(3):244-54. PubMed ID: 10874569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells.
    Yang L; Zahid M; Liao Y; Rogan EG; Cavalieri EL; Davidson NE; Yager JD; Visvanathan K; Groopman JD; Kensler TW
    Carcinogenesis; 2013 Nov; 34(11):2587-92. PubMed ID: 23843041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tumor necrosis factor-alpha on estrogen metabolism and endometrial cells: potential physiological and pathological relevance.
    Salama SA; Kamel MW; Diaz-Arrastia CR; Xu X; Veenstra TD; Salih S; Botting SK; Kumar R
    J Clin Endocrinol Metab; 2009 Jan; 94(1):285-93. PubMed ID: 18957495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
    Simard J; Sanchez R; Poirier D; Gauthier S; Singh SM; Merand Y; Belanger A; Labrie C; Labrie F
    Cancer Res; 1997 Aug; 57(16):3494-7. PubMed ID: 9270018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotoxic mechanism of tamoxifen in developing endometrial cancer.
    Kim SY; Suzuki N; Laxmi YR; Shibutani S
    Drug Metab Rev; 2004 May; 36(2):199-218. PubMed ID: 15237851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The selective estrogen receptor modulators (SERMs) raloxifene and tamoxifen improve ANP levels and decrease nuclear translocation of NF-kB in estrogen-deficient rats.
    Lamas AZ; Nascimento AM; Medeiros ARS; Caliman IF; Dalpiaz PLM; Firmes LB; Sousa GJ; Oliveira PWC; Andrade TU; Reis AM; Gouvea SA; Bissoli NS
    Pharmacol Rep; 2017 Aug; 69(4):798-805. PubMed ID: 28591668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formation of depurinating N3Adenine and N7Guanine adducts by MCF-10F cells cultured in the presence of 4-hydroxyestradiol.
    Saeed M; Rogan E; Fernandez SV; Sheriff F; Russo J; Cavalieri E
    Int J Cancer; 2007 Apr; 120(8):1821-4. PubMed ID: 17230531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
    Obrero M; Yu DV; Shapiro DJ
    J Biol Chem; 2002 Nov; 277(47):45695-703. PubMed ID: 12244117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia.
    Yang R; Ma YX; Chen LF; Zhou Y; Yang ZP; Zhu Y; Du XL; Shi JD; Ma HS; Zhang J
    Asian J Androl; 2010 Sep; 12(5):735-43. PubMed ID: 20473319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake.
    Todorova VK; Kaufmann Y; Luo S; Klimberg VS
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):285-91. PubMed ID: 20383709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the vascular endothelial growth factor and growth by estrogen and antiestrogens through Efp in Ishikawa endometrial carcinoma cells.
    Dai H; Zhang P; Zhao S; Zhang J; Wang B
    Oncol Rep; 2009 Feb; 21(2):395-401. PubMed ID: 19148513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.